Pharmaceuticals

Beyond beta-blockers, a new class of targeted therapies is revolutionizing hypertrophic cardiomyopathy care, sparking a fierce corporate race for market dominance.

A new survey reveals the staggering cost of clinical trial delays, but the real story isn't the numbers—it's the systemic breakdown of a fragmented, manual process.

The sickle cell drugmaker engineered a stunning Q2 profit, but a deep dive reveals a radical strategic bet on outsourcing its commercial backbone.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

A new fusion of real-time alerts and human expertise aims to stop financial leakage in drug copay programs, a move that could redefine revenue strategy.

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Facing a 'going concern' warning, Pulmatrix abandons its drug pipeline for a reverse merger, betting its survival on the high-risk field of longevity science.

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

Lurie Children's new facility is more than a pharmacy; it's a look into a new system where hospitals integrate business and care to survive and thrive.

As CEO Gareth Sheridan takes the stage, his company's abuse-deterrent tech, AVERSA™, promises a new front in the opioid crisis. But can it deliver?

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

With promising data for its GX-03 cream in an underserved patient group, Turn Therapeutics expands its trial, hires an ex-FDA head, and eyes a new disease.

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

With pivotal data due in September, Connect Biopharma's rademikibart could redefine acute asthma and COPD care. Can it navigate this clinical tightrope?

Journey Medical posts a stellar 23% revenue jump, nearing profitability. But beyond the headlines, a crucial SEC filing reveals a complex financial reality.

With an October FDA deadline for its lead drug, INOVIO walks a financial tightrope, betting its future on a first-in-class treatment and a broader DNA platform.